What question did this study set out to answer?

To evaluate the efficacy of long-term propranolol hydrochloride administration in reducing morbidity and recurrent coronary events in survivors of acute myocardial infarction.

November 25, 1983JAMA

A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results

View Full Paper

Ask AI

Bookmark

Why the study?

Does long-term administration of propranolol reduce coronary incidence in patients with a confirmed myocardial infarction?

Population

n=3,837 persons who had had at least one confirmed myocardial infarction

Comparison

Propranolol hydrochloride vs Placebo

Design

RCT, randomized, double-blind, placebo-controlled

Follow-up

average of 25 months

Discussion

Member takes

Implication

Long-term propranolol reduces recurrent coronary events after MI; confirms beta-blocker benefit in secondary prevention.

Key Points

To evaluate the efficacy of long-term propranolol hydrochloride administration in reducing morbidity and recurrent coronary events in survivors of acute myocardial infarction.
Randomized, double-blind, placebo-controlled clinical trial (β-Blocker Heart Attack Trial) enrolling 3,837 patients with at least one confirmed myocardial infarction.
Participants were assigned to receive long-term propranolol hydrochloride or placebo and were followed for an average of 25 months.
Coronary incidence (recurrent nonfatal definite reinfarction plus fatal coronary heart disease) was 10.0% in the propranolol group versus 13.0% in the placebo group, representing a 23% reduction.
Definite nonfatal reinfarction decreased by 15.6%, and definite or probable nonfatal reinfarction decreased by 14.7% in the propranolol arm.
Definite congestive heart failure (CHF) occurred in 14.8% vs 12.6% of patients with a CHF history (propranolol vs placebo) and 5.0% vs 5.3% without a history; angina incidence was 35.7% vs 34.4% in those without prior angina and 66% in both groups with prior angina.

Structured PICO

Does long-term administration of propranolol reduce coronary incidence in patients with a confirmed myocardial infarction?

Population

n=3,837 persons who had had at least one confirmed myocardial infarction

Intervention

Propranolol hydrochloride (long-term administration)

Comparator

Placebo

Outcome

Coronary incidence, defined as recurrent nonfatal definite reinfarction plus fatal coronary heart disease at an average of 25 months follow-upcomposite

Long-term administration of propranolol significantly reduces the incidence of recurrent nonfatal reinfarction and fatal coronary heart disease in patients with a recent myocardial infarction.

Cite This Study

A 1983 study studied this question.

synapsesocial.com/papers/6a7108df26770c2b8de0e1f2 https://doi.org/10.1001/jama.250.20.2814

View Full Paper

Ask AI

Bookmark

November 25, 1983JAMA

A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results

View Full Paper

Ask AI

Bookmark

Why the study?

Does long-term administration of propranolol reduce coronary incidence in patients with a confirmed myocardial infarction?

Population

n=3,837 persons who had had at least one confirmed myocardial infarction

Comparison

Propranolol hydrochloride vs Placebo

Design

RCT, randomized, double-blind, placebo-controlled

Follow-up

average of 25 months

Discussion

Member takes

Implication

Long-term propranolol reduces recurrent coronary events after MI; confirms beta-blocker benefit in secondary prevention.

Key Points

To evaluate the efficacy of long-term propranolol hydrochloride administration in reducing morbidity and recurrent coronary events in survivors of acute myocardial infarction.
Randomized, double-blind, placebo-controlled clinical trial (β-Blocker Heart Attack Trial) enrolling 3,837 patients with at least one confirmed myocardial infarction.
Participants were assigned to receive long-term propranolol hydrochloride or placebo and were followed for an average of 25 months.
Coronary incidence (recurrent nonfatal definite reinfarction plus fatal coronary heart disease) was 10.0% in the propranolol group versus 13.0% in the placebo group, representing a 23% reduction.
Definite nonfatal reinfarction decreased by 15.6%, and definite or probable nonfatal reinfarction decreased by 14.7% in the propranolol arm.
Definite congestive heart failure (CHF) occurred in 14.8% vs 12.6% of patients with a CHF history (propranolol vs placebo) and 5.0% vs 5.3% without a history; angina incidence was 35.7% vs 34.4% in those without prior angina and 66% in both groups with prior angina.

Structured PICO

Does long-term administration of propranolol reduce coronary incidence in patients with a confirmed myocardial infarction?

Population

n=3,837 persons who had had at least one confirmed myocardial infarction

Intervention

Propranolol hydrochloride (long-term administration)

Comparator

Placebo

Outcome

Coronary incidence, defined as recurrent nonfatal definite reinfarction plus fatal coronary heart disease at an average of 25 months follow-upcomposite

Long-term administration of propranolol significantly reduces the incidence of recurrent nonfatal reinfarction and fatal coronary heart disease in patients with a recent myocardial infarction.

Cite This Study

A 1983 study studied this question.

synapsesocial.com/papers/6a7108df26770c2b8de0e1f2 https://doi.org/10.1001/jama.250.20.2814

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark